EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 740 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab MOST POPULAR Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... May 27, 2025 Brothers Break Down After Seeing Their Parents For First Time In... October 31, 2021 EMA Recommends Extension of Therapeutic Indications for Nivolumab July 1, 2021 Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker November 23, 2021 Load more HOT NEWS Cancer in My Community: Accessing Care Through the Public Health System... Can’t Sleep? Tips for Coping with Insomnia ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to...
